Filing Details
- Accession Number:
- 0001225208-25-004942
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-09 19:34:12
- Reporting Period:
- 2025-05-07
- Filing Date:
- 2025-05-09
- Accepted Time:
- 2025-05-09 19:34:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1099800 | Edwards Lifesciences Corp | EW | Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) | 364316614 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1446989 | B. Scott Ullem | One Edwards Way Irvine CA 92614 | Cvp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2025-05-07 | 1,406 | $74.92 | 27,698 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2025-05-08 | 13,400 | $0.00 | 41,098 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2025-05-09 | 11,250 | $45.28 | 52,348 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-05-09 | 11,250 | $74.40 | 41,098 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Acquire) | Acquisiton | 2025-05-08 | 75,200 | $0.00 | 75,200 | $74.63 |
| Common Stock | Performance Rights | Acquisiton | 2025-05-08 | 13,400 | $0.00 | 13,400 | $0.00 |
| Common Stock | Employee Stock Option (Right to Acquire) | Disposition | 2025-05-09 | 11,250 | $0.00 | 11,250 | $45.28 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 75,200 | 2026-05-08 | 2032-05-07 | No | 4 | A | Direct |
| 13,400 | 2028-05-08 | No | 4 | A | Direct | |
| 0 | 2019-05-17 | 2025-05-16 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 266,318 | Indirect | By Trust |
Footnotes
- These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024.
- This transaction was executed in multiple trades at prices ranging from $74.12 to $74.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
- Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
Billionaire Hedge Funds
